The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.
A. Ribas
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche
K. B. Kim
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Research Funding - Roche/Genentech
L. M. Schuchter
No relevant relationships to disclose
R. Gonzalez
Honoraria - Roche/Genentech
Research Funding - Roche/Genentech
A. C. Pavlick
No relevant relationships to disclose
J. S. Weber
No relevant relationships to disclose
G. A. McArthur
Consultant or Advisory Role - Roche (U)
T. E. Hutson
No relevant relationships to disclose
K. T. Flaherty
Consultant or Advisory Role - Roche/Genentech
S. J. Moschos
No relevant relationships to disclose
D. P. Lawrence
No relevant relationships to disclose
P. Hersey
No relevant relationships to disclose
R. F. Kefford
Consultant or Advisory Role - Roche
B. Chmielowski
No relevant relationships to disclose
I. Puzanov
Consultant or Advisory Role - Roche
J. Li
Employment or Leadership Position - Roche
K. B. Nolop
No relevant relationships to disclose
R. J. Lee
Employment or Leadership Position - Roche
A. K. Joe
Employment or Leadership Position - Roche
J. A. Sosman
Consultant or Advisory Role - Roche
Honoraria - Roche